Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study

Diabetes, Obesity and Metabolism

Volumn 20, Issue 3, 2018, Pages 582-589

  Yuan, Zhong ^a   DeFalco, Frank J ^a   Ryan, Patrick B ^a   Schuemie, Martijn J ^a   Stang, Paul E ^a   Berlin, Jesse A ^b   Desai, Mehul ^a   Rosenthal, Norm ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

SGLT2 inhibitor; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BELOW KNEE AMPUTATION; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNITED STATES; AMPUTATION; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC ANGIOPATHY; LEG; MULTICENTER STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VASCULARIZATION;

AMPUTATION; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LEG; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; UNITED STATES;

EID: 85030843541     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13115     Document Type: Article

References (27)

1. American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40(suppl 1):S1–S135.
2. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–962.
3. National Center for Chronic Disease Prevention. National diabetes statistics report, 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed September 21, 2017.
4. World Health Organization. Global report on diabetes, 2016. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1. Accessed July 5, 2017.
5. Bruun C, Siersma V, Guassora AD, Holstein P, de Fine Olivarius N. Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidity. Diabet Med. 2013;30(8):964–972.
6. Yesil S, Akinci B, Yener S, et al. Predictors of amputation in diabetics with foot ulcer: single center experience in a large Turkish cohort. Hormones (Athens). 2009;8(4):286–295.
7. Lai YJ, Hu HY, Lin CH, Lee ST, Kuo SC, Chou P. Incidence and risk factors of lower extremity amputations in people with type 2 diabetes in Taiwan, 2001-2010. J Diabetes. 2015;7(2):260–267.
8. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–437.
9. Zhou ZY, Liu YK, Chen HL, Yang HL, Liu F. HbA1c and lower extremity amputation risk in patients with diabetes: a meta-analysis. Int J Low Extrem Wounds. 2015;14(2):168–177.
10. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309(11):F889–F900.
11. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38(12):2344–2353.
12. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358(1):28–43.
13. Davis PN, Ndefo UA, Oliver A. Dapagliflozin: a sodium glucose cotransporter 2 inhibitor for the treatment of diabetes mellitus. J Pharm Pract. 2016;29(2):165–171.
14. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):984–993.
15. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
16. US Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). 2017. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM558427.pdf. Accessed August 9, 2017.
17. INVOKANA® (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2017.
18. European Medicines Agency. PRAC concludes that diabetes medicine canagliflozin may contribute to risk of toe amputation. Risk may also apply to other medicines in the same class. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_Canagliflozin_20/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500221431.pdf. Accessed July 5, 2017.
19. European Medicines Agency. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/02/WC500222191.pdf. Accessed May 26, 2017.
20. Genkin A, Lewis DD, Madigan D. Large-scale Bayesian logistic regression for text categorization. Dent Tech. 2007;49(3):291–304.
21. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol. 1996;58(1):267–288.
22. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2):69–80.
23. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–161.
24. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
25. Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209–218.
26. Boyce RD, Ryan PB, Noren GN, et al. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf. 2014;37(8):557–567.
27. Arnold BF, Ercumen A, Benjamin-Chung J, Colford JM Jr. Brief report: negative controls to detect selection bias and measurement bias in epidemiologic studies. Epidemiology. 2016;27(5):637–641.